<?xml version="1.0" encoding="UTF-8"?><!--Transformation version 1.3--><legislativeDoc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://www.lexisnexis.com/xmlschemas/content/public/legislativedoc/1/" schemaVersion="1.0"><legislativeDocHead><citations><citeForThisResource citeDefinition="#7159#349#000054#     1#       3442.2#">Va. Code Ann. § 54.1-3442.2</citeForThisResource></citations><legislativeBodyInfo><jurisdiction><jurisSystem normalizedLongName="Virginia" normalizedShortName="VA"/></jurisdiction></legislativeBodyInfo></legislativeDocHead><legislativeDocBody><statute><level levelType="section"><anchor id="_54.1-3442.2"/><heading><desig>§ 54.1-3442.2.</desig><title>Eligibility for expanded access to investigational drugs, biological products, and devices; written, informed consent to treatment</title></heading><level levelType="paragraph"><anchor id="_a"/><heading><desig>A.</desig></heading><bodyText><p> A person shall be eligible for expanded access to investigational drugs, biological products, or devices if:</p></bodyText><level levelType="paragraph"><anchor id="_a_1"/><heading><desig>1.</desig></heading><bodyText><p> He has a terminal condition, attested to by his treating physician and confirmed by a second physician not previously involved in the treatment of the person who has conducted an independent examination of the person;</p></bodyText></level><level levelType="paragraph"><anchor id="_a_2"/><heading><desig>2.</desig></heading><bodyText><p> He has, in consultation with his treating physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration and the treating physician has determined that no reasonable opportunity exists for him to participate in an ongoing clinical trial for his terminal condition;</p></bodyText></level><level levelType="paragraph"><anchor id="_a_3"/><heading><desig>3.</desig></heading><bodyText><p> The potential benefits of use of the investigational drug, biological product, or device to treat his terminal condition are greater than the potential risks of the use of the investigational drug, biological product, or device to treat his terminal condition;</p></bodyText></level><level levelType="paragraph"><anchor id="_a_4"/><heading><desig>4.</desig></heading><bodyText><p> He has received a recommendation from his treating physician for use of an investigational drug, biological product, or device for treatment of his terminal condition; and</p></bodyText></level><level levelType="paragraph"><anchor id="_a_5"/><heading><desig>5.</desig></heading><bodyText><p> He or, if he is incapable of making an informed decision, his legally authorized representative has given written informed consent to use of the investigational drug, biological product, or device for treatment of his terminal condition or, if the person is a minor or lacks capacity to provide informed consent, his parent or legal guardian has given written informed consent to the use of the investigational drug, biological product, or device for treatment of his terminal condition.</p><p><pre/>Documentation indicating that the person meets the criteria for eligibility for expanded access to investigational drugs, biological products, or devices shall be provided by the person's treating physician and shall be included in the person's medical record.</p></bodyText></level></level><level levelType="paragraph"><anchor id="_b"/><heading><desig>B.</desig></heading><bodyText><p> Written informed consent to use of an investigational drug, biological product, or device shall include:</p></bodyText><level levelType="paragraph"><anchor id="_b_1"/><heading><desig>1.</desig></heading><bodyText><p> An explanation of the currently approved products and treatments for the person's terminal condition;</p></bodyText></level><level levelType="paragraph"><anchor id="_b_2"/><heading><desig>2.</desig></heading><bodyText><p> A statement that the person has, in consultation with his treating physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration and the treating physician has determined that no reasonable opportunity exists for the person to participate in an ongoing clinical trial for his terminal condition;</p></bodyText></level><level levelType="paragraph"><anchor id="_b_3"/><heading><desig>3.</desig></heading><bodyText><p> An explanation of the specific investigational drug, biological product, or device proposed for treatment of the person's terminal condition;</p></bodyText></level><level levelType="paragraph"><anchor id="_b_4"/><heading><desig>4.</desig></heading><bodyText><p> A description of possible outcomes resulting from use of the investigational drug, biological product, or device to treat the person's terminal condition, including a statement that new, unanticipated, different, or worse symptoms might result from and death could be hastened by the proposed treatment, based on the treating physician's knowledge of the proposed treatment in conjunction with an awareness of the person's terminal condition;</p></bodyText></level><level levelType="paragraph"><anchor id="_b_5"/><heading><desig>5.</desig></heading><bodyText><p> A statement that the person may be required to pay any costs associated with use of the investigational drug, biological product, or device; and</p></bodyText></level><level levelType="paragraph"><anchor id="_b_6"/><heading><desig>6.</desig></heading><bodyText><p> A statement that the person or, if the person is a minor or lacks capacity to provide informed consent, his parent or legal guardian consents to the use of the investigational drug, biological product, or device for treatment of his terminal condition.</p></bodyText></level></level><history><historyGroup groupType="history-citation"><historyItem><bodyText><p><citation normalizedCite="2015 VA CH 655"><content><span normalizedCite="2015 Va. Ch. 655">2015, cc. 655<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2015#000655#"/></locatorKey></locator></span></content></citation>, <citation normalizedCite="2015 VA CH 656"><content><span normalizedCite="2015 Va. Ch. 656">656<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2015#000656#"/></locatorKey></locator></span></content></citation>.</p></bodyText></historyItem></historyGroup></history></level></statute></legislativeDocBody><metadata><dc:metadata xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:identifier identifierScheme="PGUID">urn:contentItem:5K0Y-PWC0-004G-K35W-00000-00</dc:identifier><dc:source sourceScheme="productContentSetIdentifier">10816</dc:source><dc:date dateType="last-updated">2016-06-15</dc:date></dc:metadata><publicationInfo><publicationName>CODE OF VIRGINIA </publicationName><copyright>Copyright © 2016  by Matthew Bender &amp; Company, Inc. a member of the LexisNexis Group. All rights reserved</copyright></publicationInfo><hierarchy><hierarchyLevel levelType="title"><heading><desig>TITLE 54.1.</desig><title>PROFESSIONS AND OCCUPATIONS</title></heading><hierarchyLevel levelType="subtitle"><heading><desig>SUBTITLE III.</desig><title>PROFESSIONS AND OCCUPATIONS REGULATED BY BOARDS WITHIN THE DEPARTMENT OF HEALTH PROFESSIONS</title></heading><hierarchyLevel levelType="chapter"><heading><desig>CHAPTER 34.</desig><title>DRUG CONTROL ACT</title></heading><hierarchyLevel levelType="article"><heading><desig>ARTICLE 4.1.</desig><title>EXPANDED ACCESS TO INVESTIGATIONAL DRUGS, BIOLOGICAL PRODUCTS, AND DEVICES.</title></heading></hierarchyLevel></hierarchyLevel></hierarchyLevel></hierarchyLevel></hierarchy><classification classificationScheme="legal"><classificationItem><className>Criminal Law &amp; Procedure</className><classCode>Z3VpZD11cm46dG9waWM6NEU0RkE1OUQwNUQwNDgxODhEODZCMjkzOTg3NThBNzk7cGFyZW50Z3VpZD0</classCode><classificationItem><className>Substance Abuse Programs</className><classCode>Z3VpZD11cm46dG9waWM6RTVFMjYwRkVBNUYwNDI4MUE2NEY3RUZBMkZDQUYwNjU7cGFyZW50Z3VpZD11cm46dG9waWM6QUM4NjRENzc2NUY4NEQwMUEyQTdBNkM4MDhEQURCQjU</classCode></classificationItem></classificationItem><classificationItem><className>Healthcare Law</className><classCode>Z3VpZD11cm46dG9waWM6NkUxMkVDQjJDOEY5NDVDQ0E5NTFEMTlDMjIwNzVERjc7cGFyZW50Z3VpZD0</classCode><classificationItem><className>Consent by Guardians &amp; Parents</className><classCode>Z3VpZD11cm46dG9waWM6MjI4NDcxOEQ4ODcxNDRBQkE4MEUzQjY4NEVDNDNGMjQ7cGFyZW50Z3VpZD11cm46dG9waWM6OEQ4NDdDRTY1QTdDNEZFODhDREYxQTRGMDhGQURDMzU</classCode></classificationItem><classificationItem><className>Experimental Treatment</className><classCode>Z3VpZD11cm46dG9waWM6QUNCMUU5MDQ3RUYwNDA0NkE3QzQ2MENFQzhBODYwNDQ7cGFyZW50Z3VpZD11cm46dG9waWM6NzYzODNGRDdGNkNDNDE4MTlDNTU4REQ1MEE3MUNFOEI</classCode></classificationItem><classificationItem><className>General Overview</className><classCode>Z3VpZD11cm46dG9waWM6REIzOUJERjYzNEE1NEI2QUFENjZDQTBERkIzNTk0RjY7cGFyZW50Z3VpZD11cm46dG9waWM6NjM2NTg4ODQ2MEU0NENDOUE4NzlDN0E2QjM5MjJFQjg</classCode></classificationItem><classificationItem><className>General Overview</className><classCode>Z3VpZD11cm46dG9waWM6OTgwNUI4RTJENUI0NEIzOEJGNTUwMzZCODFEQjlGQjc7cGFyZW50Z3VpZD11cm46dG9waWM6OEQ4NDdDRTY1QTdDNEZFODhDREYxQTRGMDhGQURDMzU</classCode></classificationItem><classificationItem><className>Informed Consent</className><classCode>Z3VpZD11cm46dG9waWM6M0E0NEEwMjRGNDcxNEI2RUIxRkYyMDY1RUY3QkJBMUU7cGFyZW50Z3VpZD11cm46dG9waWM6OEQ4NDdDRTY1QTdDNEZFODhDREYxQTRGMDhGQURDMzU</classCode></classificationItem></classificationItem></classification><classificationGroup classificationScheme="indexing-terms"><classification classificationScheme="legal"><classificationItem><className>Business &amp; Corporate Compliance</className><classCode>Z3VpZD11cm46dG9waWM6MUFEMUQ2QTA1OUZCNEE5RjkzNTA2RERFMUNEOTk1RTI7cGFyZW50Z3VpZD0</classCode><classificationItem score="90"><className>Businesses &amp; Corporations</className><classCode>Z3VpZD11cm46dG9waWM6QjA4OEVGODBENzY4NDcxM0IyQzA1OTEwQzVDODRBOUE7cGFyZW50Z3VpZD11cm46dG9waWM6MUFEMUQ2QTA1OUZCNEE5RjkzNTA2RERFMUNEOTk1RTI</classCode></classificationItem></classificationItem></classification></classificationGroup></metadata></legislativeDoc>